- Home
- MNDR vs NCNA Comparison
MNDR vs NCNA Comparison
Compare MNDR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNDR | NCNA |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 7.6M |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MNDR | NCNA |
|---|---|---|
| Price | $1.77 | $4.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.9M | 64.5K |
| Earning Date | 10-31-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,646,739.00 | N/A |
| Revenue This Year | $608,852.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $2.78 |
| 52 Week High | $40.00 | $330.00 |
Technical Indicators
Market Signals| Indicator | MNDR | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 60.10 |
| Support Level | $1.85 | $3.82 |
| Resistance Level | $2.92 | $4.35 |
| Average True Range (ATR) | 0.55 | 0.28 |
| MACD | -0.05 | 0.12 |
| Stochastic Oscillator | 6.43 | 95.99 |
Price Performance
Historical ComparisonAbout MNDR Mobile-health Network Solutions Class A Ordinary Shares
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services, and the Sale of medicine and medical devices. The majority of the company's revenue is derived from the Telemedicine and other services segment. Geographically, it derives revenue from Singapore.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.